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Besides anti-drug antibodies, anti-nuclear antibodies and anti-DNA antibodies are often
induced in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors.
We examined the association between immunogenicity, autoantibody production, and
serum cytokine profiles in patients with rheumatoid arthritis treated with infliximab. Japa-
nese patients with rheumatoid arthritis (n = 57) were retrospectively examined. Serum
trough levels of infliximab, anti-drug antibody, anti-nuclear antibody, and anti-DNA (Farr),
anti-single-stranded DNA and anti-double-stranded DNA antibodies were measured. Inter-
leukin-6, interferon-γ, interferon-α, and B-cell activating factor levels were also measured in
the same sera. Then, we validated the association between anti-drug antibody and these
serum markers along with clinical response to infliximab. Anti-drug antibodies developed in
twenty-one patients (36.8%), whose serum trough levels of infliximab were significantly
lower than those in anti-drug antibody-negative patients (0.09 ± 0.03 vs. 2.48 ± 0.326 μg/
mL, p < 0.0001). There were no significant differences in clinical backgrounds between the
two groups. The anti-drug antibody-positive patients were more likely to develop anti-
nuclear antibody titers of ×160 compared to the negative patients (14 to 57% vs. 17 to
33%). In addition, anti-DNA antibodies (Farr) (from 1.5 ± 0.4 to 35 ± 17 IU/mL, p = 0.0001),
especially IgM-anti-double stranded DNA antibody (from 5.1 ± 0.7 to 41 ± 8.9 IU/mL, p <
0.0001), and IgG-anti-single stranded DNA antibody (from 13 ± 1.1 to 35 ± 13, p = 0.0145)
were significantly increased in anti-drug antibody-positive but not in negative patients.
Moreover, the anti-drug antibody-positive, but not the negative patients, showed significant
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increased levels of interferon-α (from 248.7 ± 102.3 to 466.8 ± 135.1 pg/mL, p = 0.0353)
and B-cell activating factor (from 1073 ± 75.1 to 1387 ± 136.5 pg/mL, p = 0.0208) following
infliximab treatment. The development of anti-drug antibody against infliximab and lupus-
like autoantibody production in patients with rheumatoid arthritis treated with infliximab can
be linked each other along with increased lupus-associated cytokine levels including type I
interferons.
Introduction
TNF inhibitors (TNFi) has been advantageous for many individuals with rheumatoid arthritis
(RA). To date, five TNFis have been approved in Japan for the treatment of RA: infliximab
(IFX), adalimumab, etanercept, golimumab, and certolizumab pegol. However, in some
patients, an immune response is triggered by the TNFi, which results in the formation of anti-
drug antibodies (ADAs). Immunogenicity is a harmful immunological reaction triggered by
biological agents including TNFi. The prevalence of ADAs highly varies in studies of TNFi [1,
2], whereas the assay used for the detection of ADAs in a given study also influences the fre-
quency of ADAs [3]. Development of ADAs is one of the causes of impaired clinical response
to treatment with IFX or adalimumab in patients with RA [1, 4–10], and is also associated with
increased frequency of clinical adverse events such as infusion reactions [11–13]. The develop-
ment of ADAs have also been reported in other TNFi including etanercept [14–17], golimu-
mab [18, 19] and certolizumab pegol [20–23], but the numbers of ADA-positive patients were
too small to determine whether these ADAs were associated with an insufficient clinical
outcome.
Autoimmune phenomena such as lupus-like syndrome or autoantibody production have
also been observed in RA patients receiving TNFi, and some of these patients have shown
insufficient clinical response [24]. However, the association between immunogenicity and
autoimmunity has never been fully examined in RA patients; there has only been one study of
such an association and that study showed a possible association between the two phenomena
in psoriasis patients who received TNFi [25].
In the present study, we assessed IFX immunogenicity in Japanese RA patients treated with
IFX and compared the profiles of autoantibody production before and after IFX treatment. We
found that anti-nuclear antibodies (ANAs) and anti-DNA antibodies (Abs) were more fre-
quently induced and their serum titers were higher in ADA-positive compared with ADA-neg-
ative patients. In addition, for the ADA-positive but not ADA-negative patients, the serum
levels of interferon-α2 (IFN-α2) and B-cell activating factor (BAFF) were significantly
increased after the initiation of IFX treatment, whereas the serum interleukin-6 (IL-6) and
IFN-γ levels remained high levels. These data suggest that both ADA against IFX and lupus-
like autoantibody production can be associated with each other, and type I IFN signals which
might be driven by anti-TNF treatment can also impact on their developments.
Materials and Methods
Patients
Japanese RA patients treated with IFX at Kyoto University Hospital from 2004 to 2013 were
initially picked up, and then patients whose serum samples were taken at least two time points,
pre- and post-IFX treatment, were enrolled and retrospectively examined. All patients fulfilled
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the 1987 American College of Rheumatology classification criteria [26] and provided written
informed consent. Patient information was extracted from electronic medical records. Stocked
serum samples, which had been taken at multiple time points before and after the treatment,
were used. The serum samples taken just before the first administration, 4 weeks after the initial
treatment, and every 4 or 8 weeks thereafter were used. Serum samplings were missed at some
points in some patients, and statistical analyses were performed on only available sera; the
intention-to-treat approach was not used. For patients who discontinued IFX, but did not
switch to the other biologic agents, sera obtained till originally scheduled next timing of IFX
administration were used. For patients who switched to other biologics, sera obtained until
next biologic disease modifying anti-rheumatic drugs (DMARDs) were administered were
used. The Institutional Review Board of the Graduate School of Medicine, Kyoto University
and Kyoto University Hospital approved the present study.
Assessment of immunogenicity
Serum IFX trough levels and ADAs against IFX were measured using enzyme-linked immuno-
sorbent assay (ELISA) and radioimmunoassay, respectively, at Sanquin Diagnostic Services
(Plesmanlaan, CX, Amsterdam) [3].
Autoantibody detection
ANAs and anti-DNA Abs (Farr) were measured using semi-quantitative indirect fluorescence
assay and radioimmunoassay, respectively. IgG-anti-single-stranded-DNA (anti-ssDNA) and
IgG-anti-double-stranded DNA (anti-dsDNA) Abs were measured by ELISA using MESA-
CUP™DNA-II test ss and ds (Medical & Biological Laboratories Co., Ltd., Nagoya, Japan),
respectively. IgM-anti-dsDNA Ab was measured using ELISA (Alpha Diagnostic International,
Texas, USA).
Serum cytokine measurement
Serum cytokines were measured using the Milliplex MAPMultiplex Kit (Merck Millipore,
Darmstadt, Germany) and obtained data were analyzed using Bio-Plex™ 200 (BIO RAD,
Tokyo, Japan).
Statistical analyses
All the serum parameters described above were measured using the same serum samples of
given patients. Data are presented as mean ± SEM otherwise specified, and were compared
using the Chi-square test, Fisher’s exact test, and the Mann-Whitney U test for two-group
comparisons, and the Kruskal-Wallis test and Dunn’s multiple comparison test for multiple
group comparisons. Spearmann’s correlation coefficient was calculated for changes of the
obtained serum sample data and changes of DAS28-ESR. A log-rank test was used for assess-
ment of the cumulative drug retention rate, and the proportion of ADA and ANA at different
time points. P values< 0.05 were considered significant. All the statistical analyses were per-
formed using GraphPad Prism 7 (GraphPad Software, Inc.).
Results
Study population
The clinical features of enrolled patients are summarized in Table 1. Fifty-five patients
received IFX as a first biologic DMARD. We divided the patients into ADA-positive and
ADA-negative groups; ADA positive group was consisted of patients who developed ADA
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during the observation, and ADA-negative group was consisted of patients who did not
develop ADA throughout the observation. Only two patients were not biologic-naïve. One is
included in the ADA-negative group with high disease activity, who previously received toci-
lizumab as a clinical trial and switched to etanercept, both of which were ineffective. The
other is included in the ADA-positive group with high disease activity, who had previously
received tocilizumab, and switched to IFX at the timing of the clinical trial end. ADA devel-
oped in 21 patients (36.8%) during observation. The median ADA titer was 96.0 (12–35,000)
AU/mL. Mean duration of follow-up were 61.6 (12.8–117.9) and 65.3 (16.6–115.5) months in
ADA-negative and ADA-positive group, respectively. There were no differences in patients’
backgrounds between the two groups. All the patients were administered with methotrexate
(MTX); MTX doses did not significantly differ between the two groups. The frequency and
doses of concomitant oral prednisolone were also not different between these groups. All
patients had moderate to high disease activities; there was no difference in disease activity
score 28-erythrocyte sedimentation rate (DAS28-ESR) between the two groups before the ini-
tiation of IFX treatment. Three patients had transiently withdrawn from IFX treatment for
more than 3 months due to infection (pneumonia, sepsis) or suspected malignancy, and they
later developed ADAs following re-administration of IFX (odds ratio 13.8, p = 0.046, Fisher’s
exact test).
Table 1. Clinical features of the patients enrolled in this study.
All patients ADA (+) ADA (-) P value
Numbers of patients (%) 57 21 (38%) 36 (62%) -
Age, years old 51.2±13.8 53.8±12.7 49.7±14.4 0.294b
Female (%) 45 (78.9) 16 (76.2) 29 (80.6) 0.927c
Disease duration 6.73±0.89 6.35±1.12 6.95±1.26 0.766 b
Steinbrocker's Stage I+II (%) 58 66 53 0.819d
RF (U/mL) 262±158 89.7±15.4 372±258 0.559 b
Sjögren’s syndrome 2 0 2 0.526 c
MTX (%) 57 (100) 21 (100) 36 (100) NS
MTX dosage (mg/week) 8.28±2.15 8.19±1.78 8.33±2.37 0.993 b
sDMARDs except for MTX 9 (15.8) 3 (14.3) 6 (13.0) 1 c
SASP (%) 5 (8.92) 1 (5.26) 4 (10.5) 0.642 c
BUC (%) 1 (1.79) 0 (0) 1 (2.63) 1 c
TAC (%) 3 (5.36) 2 (10.5) 1 (2.63) 0.548 c
PSL (%) 29 (51.8) 11 (57.9) 18 (47.4) 1 c
PSL dosage (mg/day) 3.03±4.18 3.64±3.88 2.67±4.35 0.443 b
Initial DAS28-ESR 4.81±1.63 5.20±1.54 4.57±1.66 0.264 b
As a 1st biologic (%) 55 (96.5) 20 (95.2) 35 (97.2) 1 c
Discontinuation > 3 monthsa 3 (5.26) 3 (14.3) 0 (0) 0.046 c
Mean duration of follow-up (months) 63.0 65.3 61.6 0.268 b
a Patients who discontinued IFX therapy for longer than 3 months.
b Mann-Whitney U test,
c Fisher’s exact test,
d Chi-square test. Data are presented mean ± SD.
ADA, anti-drug antibody; RF, rheumatoid factor; MTX, methotrexate; sDMARDs, synthetic disease modifying anti-rheumatic drugs; SASP,
salazosulfapyridine; BUC, bucillamine (penicillamine derivatives); TAC, tacrolimus; PSL, prednisolone. None of our patients were treated with
hydroxychloroquine. DAS28-ESR, disease activity score 28-erythrocyte sedimentation rate
doi:10.1371/journal.pone.0162896.t001
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ADA was associated with reduced clinical response
ADAs were detected as early as 2.3 months after the initiation of IFX treatment. Of the patients
who developed ADAs, 42.9% developed within the first six months and 80.9% developed
within the first year of IFX treatment (Median 7.2 months). When we compared ADA-positive
sera which showed seroconversion for the first time with ADA-negative sera which were taken
at the time points (6.1 ± 1.3 months) when ADA-negative patients presented impaired clinical
response, serum trough levels of IFX were significantly decreased in the ADA-positive sera
compared with the ADA-negative sera (0.09 ± 0.03 vs. 2.48 ± 0.33 μg/mL; p< 0.0001). As had
been reported previously, both the improvement of DAS28-ESR score at 6 months (-2.02± 0.26
ADA-negative vs. -1.27 ± 0.36 ADA-positive; p = 0.14) and the treatment efficacy, which was
defined as low-disease activity (LDA) or remission, at 6 months were worse in the ADA-posi-
tive than in the ADA-negative group (Fig 1A). As a result, the cumulative drug retention rate
of at 400 weeks was also lower in ADA-positive patients (Fig 1B). Primary or secondary failure
was the most frequent cause of discontinuation of IFX treatment in both groups, whereas the
rate of drug withdrawal by achieving remission was slightly higher in the ADA-negative group
(S1 Fig). As was expected, an infusion reaction was observed in 3 patients, all of whom had
ADA at the time of the event. Of the alternative treatments adopted after the development of
ADAs, switching biologic agents gave the highest DAS28-ESR improvement (S2 Fig).
ANAs developed more frequently in ADA-positive than in ADA-negative
patients
To clarify the relationship between autoimmune phenomena and ADA formation, we first
measured ANA titers in the sera before and after IFX treatment. The ADA-positive patients
were more likely to develop ANA titers ×160 compared to the ADA-negative patients (14 to
57% vs. 17 to 33%). The average time for ANA titers to increase significantly, which was
defined as at least doubled in consecutive measurements for patients with ×80 of base line
ANA titers or at least quadrupled in consecutive measurements for patients with ×40 of base
line ANA titers, from the initiation of IFX treatment was 15.4 ± 2.9 months. It is noteworthy
that the median time to seroconversion was similar for ANA (7.9 months) and ADA (9.6
months) in the both ANA and ADA-positive patients (Fig 2A). The homogeneous/speckled
pattern was the most frequently observed ANA staining pattern before IFX treatment. After
the initiation of IFX treatment, most of the staining patterns turned to be homogenous/speck-
led pattern in both groups (Fig 2B). As homogenous/speckled pattern reflects the development
of anti-DNA or anti-extractable nuclear antigen (ENA) Abs, we measured anti-ENA Abs
including lupus-specific autoantibodies, such as anti-Sm and anti-U1-RNP Abs; however,
none of the patients developed these lupus-specific anti-ENA Abs as well as lupus manifesta-
tions during the observation periods. Although some patients in both ADA-positive and nega-
tive group had anti-SS-A/La, or anti-SS-B/Ro Abs, there was no difference in the frequency
between the groups (4.8% in ADA-positive group vs 8.3% in ADA-negative group; p = 1.00,
Fisher’s exact test), and none of the patients developed these Abs after the initiation of IFX
treatment.
Anti-DNA Abs were more likely to develop in ADA-positive patients than
in ADA-negative patients
We next measured anti-DNA Abs (Farr) in the pre- and post-IFX sera. The ADA-positive sera
were more likely to show abnormal anti-DNA Ab (Farr) levels (upper limit of normal value 6
IU/mL) than the ADA-negative sera (12/21 (57%) vs. 8/36 (22%), p = 0.011, Fisher’s exact test)
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Fig 1. Anti-drug antibody (ADA) is associated with reduced clinical response. (A) Treatment efficacy defined as low disease activity
(LDA) or remission at 6 months. Percentages and absolute numbers of each group of patients are indicated below the graphs. ADA
positivity was based on the assessment of 6 months. Fisher’s exact test was used for comparison. (B) Cumulative drug retention rates. A
log-rank test was used for comparison between the two groups.
doi:10.1371/journal.pone.0162896.g001
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Fig 2. The association between ADA and ANA. (A) The proportion of ADA (n = 21) and ANA ( ×160, n = 15) positive patients at
different time points after IFX treatment in the ADA-positive group. A log-rank test was used for comparison between ADA and ANA
curves. (B) Changes in the ANA staining pattern before (pre) and after (post) IFX. Numbers in bar graphs indicate percentages of
patients with Hom/Spe pattern of FANA. None, ANA titer was ×40; Hom/Spe, homogenous/speckled. The chi-square test was
used for comparison. * p = 0.037 (ADA-negative group) and p = 0.032 (ADA-positive group), ns: not significant.
doi:10.1371/journal.pone.0162896.g002
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during the observation periods. Moreover, the ADA-positive but not ADA-negative patients
developed significantly increased levels of anti-DNA Ab (Farr) during IFX treatment, and the
highest post-treatment levels were significantly higher compared with the ADA-negative
patients (Fig 3A). Interestingly, there was no difference in the levels of IgG-anti-dsDNA Ab
Fig 3. The association between ADA and anti-DNA Ab. The baseline (pre) and the peak (post) values of anti-DNA Ab (Farr) (A), IgG-anti-
dsDNA Ab (B), IgM-anti-dsDNA Ab (C), and IgG-anti-ssDNA Ab (D). The upper limit normal values are indicated by dashed lines. The post
values are the highest titers observed during the follow-up periods. Each dot represents a single serum sample, and the data are presented as
mean ± SEM. A paired t-test for intra-group comparison or the Mann-Whitney test for inter-group comparison was used. ns: not significant.
doi:10.1371/journal.pone.0162896.g003
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between the two groups (Fig 3B). As the Farr assay detects both IgG and IgM Abs [27], and sev-
eral groups have reported that TNFi induces IgM-anti-dsDNA Abs [28, 29], we measured
IgM-anti-dsDNA Ab levels in the same sera (Fig 3C). Although both the ADA-positive and
ADA-negative patients developed significantly increased levels of IgM-anti-dsDNA Ab after
the initiation of IFX treatment, post-treatment levels were higher in the ADA-positive patients.
In addition, IgG-anti-ssDNA Ab levels were also significantly increased after the initiation of
IFX treatment in the ADA-positive group, although the difference of Ab titers between the
groups was not significant (Fig 3D). Moreover, we found weak but positive correlations
between ADA titers and titers of ANA (r = 0.282, p = 0.037), anti-DNA Ab (Farr) (r = 0.229,
p = 0.0014), IgM-anti-dsDNA Ab (r = 0.277, p = 0.0002), and IgG-anti-ssDNA Ab (r = 0.155,
p = 0.026). We also found that anti-DNA Ab (Farr) titers correlated better with IgM-anti-
dsDNA Ab titers (r = 0.500 p = 0.0001) than IgG-anti-dsDNA Ab titers (r = 0.246, p = 0.0026),
which further supports that the increased levels of serum anti-DNA Ab (Farr) reflected the
increase of IgM-anti-dsDNA Ab in our cohort.
Type I IFNs are also increased in the sera of ADA-positive patients
To investigate the underling mechanisms that can link immunogenicity and lupus-like autoan-
tibody production, we measured the levels of various cytokines in the same sera in which the
ADAs and autoantibodies were measured. We used sera taken 12 months after the initiation of
treatment, as the most of ADA had developed within 12 months and ANA had also developed
in the same timing (Fig 2A). There was no significant difference in the initial levels of cytokines
we measured between the groups except for those of BAFF, which were significantly higher in
the ADA-negative patients (Fig 4). Of the cytokines we measured, IL-6, IFN-γ, and IFN-α2
showed significantly higher levels in the ADA-positive than in the negative group after IFX
treatment. Moreover, IFN-α2 levels were significantly increased after IFX treatment in the
ADA-positive patients but not in the ADA-negative patients. One of the IFNα signatures,
BAFF, also showed same trends as IFN-α2, although post-treatment levels were not different
between the groups. While the ADA-positive patients kept high levels of IL-6 despite the IFX
treatment, a significant decrease in IL-6 levels was observed in the ADA-negative patients fol-
lowing IFX treatment (Fig 4). In addition, changes of IL-6 level from pre-IFX to post-IFX posi-
tively correlated with DAS28-ESR changes, while IFN-γ and IFN-α2 changes did not. The
changes of BAFF levels correlated with DAS28-ESR changes only weakly (S3 Fig). Intriguingly,
post-treatment levels of both IFN-α2 and BAFF were higher in ANA-positive, than ANA-nega-
tive patients among ADA-positive group (S4 Fig), and IFN-α2 showed weak positive correla-
tion with ADA (r = 0.314, p = 0.019) and ANA (r = 0.338, p = 0.012). Together these results
indicated that type I IFNs can be linked to both immunogenicity and lupus-like autoantibody
production in RA patients undergoing IFX treatment.
Discussion
In the present study, we found an association between immunogenicity and lupus-like autoan-
tibody production induced by IFX treatment of RA. To the best of our knowledge, this is the
first report which describes the relationship between these immunological phenomena in RA
patients treated by TNFi.
Patients who developed ADA showed markedly decreased trough levels of IFX, reduced
clinical response, and poor cumulative drug retention rate compared to those who did not
developed ADA; these data are comparable with previous reports [7]. Since all of the patients
received MTX and the mean MTX dose did not differ between the two groups, we were unable
to assess the influence of MTX on the immunogenicity of IFX in the present study. However, it
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is suggested that an MTX dose of up to 8 mg per week, which was the past-approved maximum
dose in Japan, may have less impact on the immunogenicity of IFX compared to more than 8
mg per week of dosage. On the other hand, in the CONCERTO study, adalimumab concentra-
tions increased with an ascending dose of MTX of up to 10 mg per week and treatment efficacy
was equivalent between 10 and 20 mg of weekly MTX in combination with adalimumab [30].
Therefore, it may be speculated that at least 10 mg of weekly MTX is effective for preventing
immunogenicity in IFX treatment. Although we did not measure baseline TNF-α levels, which
would be useful to predict patients who need higher doses of TNFi to achieve enough trough
levels of TNFi, it may worth studying whether baseline TNF-α levels affects the development of
ADA against a given TNFi.
Fig 4. Serum cytokine levels before and 12 months after IFX treatment. The pre- and post-treatment levels of IL-6, IFN-γ, IFN-α2 and BAFF were
compared between ADA-positive (+) and ADA-negative (-) groups. Data are presented as mean + SEM. A paired t-test for intra-group comparison and
the Mann-Whitney test for inter-group comparison were used.
doi:10.1371/journal.pone.0162896.g004
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Previous data regarding the immunogenicity of IFX and adalimumab suggested that the
majority of treated patients developed ADAs within the first 6 months of treatment [31]. On
the other hand, most of our patients also developed ADAs within one year after the initiation
of IFX treatment and half of them had developed ADAs within 6 months. Since this was a ret-
rospective study and blood samples stored in the early phases of IFX treatment were limited,
the frequency of ADA-positive patients might be higher in earlier phases after the initiation of
IFX treatments than that suggested by the present data. Interestingly, the time to seroconver-
sion was similar for ADA and ANA in the ADA-positive group (Fig 2A). This finding sug-
gested that ADA might develop together with ANA in RA patients treated with IFX. This
possibility is also supported by a recent study that showed an association between the serocon-
version of ANA and secondary non-response to the TNFi [32].
The ADA-positive patients developed abnormal levels of serum ANA and anti-DNA Ab
(Farr) more frequently than the ADA-negative patients after the initiation of IFX treatment.
Since ADA-positive sera presented higher titers of anti-DNA Ab than ADA-negative sera (Fig
3A), the higher anti-DNA Ab titers are, the more likely ADAmay develop although an absolute
cut-off values are still unclear and correlation between ADA levels and anti-DNA Ab titers
were weak. Both groups of patients developed IgG-anti-ssDNA Abs after the IFX treatment,
which might partly explain the altered post-treatment expression of ANAs because the isotype
of ANAs commonly measured is of IgG isotype. IgM-anti-dsDNA Ab, but not IgG-anti-
dsDNA Ab, was also induced in patients who received IFX and was more significantly elevated
in the ADA-positive patients. On the other hand, lupus-specific autoantibodies, such as anti-
Sm or anti-U1-RNP Abs, were not developed in the patients, and none of the patients exhibited
lupus-associated manifestations. These data indicated that the autoantibody induction
observed in the present study was neither due to the concomitant existence of SLE in RA
patients nor to a new onset of SLE, which included anti-TNF-induced lupus or drug-induced
lupus [33]. It was previously demonstrated that most of anti-dsDNA Abs generated during the
treatment of RA are of the IgM isotype [29, 34], and are not associated with other serological
or clinically relevant signs of lupus [28]. On the other hand, the most prevalent isotype of ADA
is of IgG isotype [3]. Therefore, an induced B-cell population that can further switch to IgG
production may also have some roles in IgM-autoantibody production [29, 34], although fur-
ther studies are needed to examine the exact roles of each Ig isotype and association among dif-
ferent isotype-producing B cells.
In the present study, we found that serum IFN-α2 was significantly increased in ADA-posi-
tive patients after IFX treatment. Type I IFNs, especially IFN-α, are known to be associated
with various autoimmune diseases including SLE and are mainly produced by plasmatoid den-
dritic cells (pDCs) [35]. Autoantibodies associated with IFN-α production in SLE include anti-
dsDNA Ab, as well as anti-RNA binding protein Abs [36]. Type I IFNs have also been sug-
gested to be associated with Sjögren’s syndrome [37]; however, there was no difference in the
frequency of Sjögren’s syndrome between the ADA-positive and ADA-negative groups in our
cohort. It is also known that TNF-α inhibits the generation of pDCs and type I IFN secretion
by pDCs, and in vitro culture of peripheral blood mononuclear cells with a TNFi increases
IFN-α expression [38]. Moreover, a recent study of a murine model of TNFi-induced lupus,
which is a TNF deficient mouse, showed constitutively increased numbers of circulating pDCs,
developed high levels of autoantibodies, and type I IFNs and their related genes by chronic toll-
like receptor-7-driven inflammation with pristane [39]. One of the IFN-α-regulated genes
BAFF are known to be highly expressed in peripheral blood mononuclear cells of about 60% of
adult SLE patients [40]. Although post-IFX levels were not different between ADA-negative
and ADA-positive groups, the latter developed significantly higher levels of serum BAFF after
IFX treatment. All these findings indicated that the levels of TNF-α and IFN-α (and its
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signatures) might influence the development of lupus-like autoantibody production following
treatment with TNFi in humans. However, it is necessary to compare the changes of IFN-α2
and BAFF levels between IFX-continued and -discontinued groups in relation to ADA and
ANA using enough number of patients in the future study to elucidate the relationships
between serum cytokine imbalance and autoantibody production more clearly.
It is noteworthy that IL-6 induce the terminal differentiation of B cells into plasma cells and
is important for plasma-cell survival [41], and type I IFNs induce IL-6 production from DCs
[42]. Becker et al. reported that IFN-α2 levels were closely correlated with various cytokines
including IL-6 in SLE patients with moderate activity [43]. The positive correlation between
IL-6 and DAS28-ESR observed in our cohort indicated that increased IL-6 levels reflected
increased RA activity, whereas higher levels of IL-6 in the ADA-positive group compared to
the ADA-negative group might also reflect increased IFN-α2 activity. Moreover, It is known
that T cells activated by type I IFNs are skewed towards Th1 immune responses with IFN-γ
production [42]. Therefore, our results that the serum IFN-γ levels were higher in the ADA-
positive than in the ADA-negative group after IFX treatment, and that there was no correlation
between the levels of IFN-γ and DAS28-ESR, might indicate type I IFN-driven helper T-cell
skewing in ADA-positive patients. Although we were not able to assess the cytokine levels at
the time points earlier than 12 months due to the limited numbers of samples, cytokine levels
at earlier time points will be necessary to define the underlining mechanism of both immuno-
genicity and lupus-like autoantibody production in the future study. In addition, as we were
not able to evaluate any biomarkers described above in enough number of sera before serocon-
version except for baseline in patients with ADA, it is also expected to evaluate sera just before
seroconversion of ADA to delineate precise changes of these biomarkers.
Although RA patients who received less immunogenic TNFi, such as etanercept or golimu-
mab, also developed lupus-like autoantibody production [32, 44], the frequency and relative
odds ratio were higher in RA patients who received IFX or adalimumab compared to ones who
received etanercept [45]. This fact also posts the possible association between immunogenic
property of a given TNFi and development lupus-like autoantibody production.
We acknowledge that this was a retrospective study, the number of patients was limited, the
doses of MTX and IFX used were lower than the doses used today, and lack of intention-to-
treat approaches might cause bias to some degree. Furthermore, sera just before and after sero-
conversion of ADA were not able to be compared due to limited numbers of sera used in this
study. Therefore, we must say that further prospective studies with enough number of patients
are necessary to delineate the association between immunogenicity and lupus-like autoanti-
body production.
Conclusions
We suggest that the development of ADA against IFX can be linked to lupus-like autoantibody
production without clinical manifestations of lupus and subsequent insufficient clinical
response. Moreover, type I IFNs might be involved in the production of both ANA and ADA
in RA patients treated with IFX.
Supporting Information
S1 Fig. The causes associated with discontinuation of IFX. Failure included primary and sec-
ondary treatment failures. Other causes included infections, interstitial pneumonia, economical
reasons. Chi-square test was used for two group comparison.
(TIF)
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S2 Fig. Comparison of DAS28-ESR improvements mediated by alternative treatments to
IFX. Improvement in the DAS28-ESR score 6 months after the time of failure of IFX treatment
in ADA-positive patients who were administered either 20 mg intravenous prednisolone (i.v.
PSL) as premedication or increased doses of IFX (Dose-up; the mean dose of the last adminis-
tration was 4.77±0.24 mg/kg), or whose treatment was changed to other biologic disease modi-
fying anti-rheumatic drugs (Bio-switch) including etanercept (n = 4), adalimumab (n = 1), and
tocilizumab (n = 3). Data are presented as mean ± SEM. Kruskal-Wallis and Dunn’s multiple
comparison tests were used for comparisons. ns: not significant.
(TIFF)
S3 Fig. Correlations between changes of cytokine levels (IL-6, IFN-γ, IFN-α2, and BAFF)
and the changes of DAS28-ESR scores. The correlations between changes of cytokine levels
shown in Fig 4 and the changes of disease activity score (DAS28)-erythrocyte sedimentation
(ESR) were calculated for the same time point. Each dot represents data from a single patient.
Spearmann r and approximate p values are indicated.
(PNG)
S4 Fig. Post-IFX levels of IFN-α2 and BAFF. Post-IFX levels of IFN-α2 and BAFF levels were
compared among ADA-negative with or without ANA and ADA-positive with or without
ANA patients. Each dot represents data from a single patient. Data are presented as mean ±
SEM. Mann-Whitney test was used for comparison.
(TIF)
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